| Date | Panel | Item | Activity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacogenomics_Paediatric v0.33 | HLA-A |
David Metz changed review comment from: Carbamazepine/Oxcarbazapine. HLA-B*15:02 or HLA-A*31:01 a/w increase risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). HLA-A*31:01 a/w with risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE).; to: PMID 29392710 HLA-A*31:01 positive: Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE (maculopapular exanthema) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | HLA-A |
David Metz changed review comment from: Carbamazepine/Oxcarbazapine. At least one copy of either HLA-B*15:02 or HLA-A*31:01 associated with increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). HLA-A*31:01 also associated with risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE).; to: Carbamazepine/Oxcarbazapine. HLA-B*15:02 or HLA-A*31:01 a/w increase risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). HLA-A*31:01 a/w with risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE). |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | HLA-A | David Metz commented on gene: HLA-A | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.12 | HLA-A | Zornitza Stark Marked gene: HLA-A as ready | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.12 | HLA-A | Zornitza Stark Gene: hla-a has been classified as Green List (High Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.12 | HLA-A | Zornitza Stark Classified gene: HLA-A as Green List (high evidence) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.12 | HLA-A | Zornitza Stark Gene: hla-a has been classified as Green List (High Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.11 | HLA-A |
Zornitza Stark gene: HLA-A was added gene: HLA-A was added to Pharmacogenomics_Paediatric. Sources: Expert list Mode of inheritance for gene: HLA-A was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted Phenotypes for gene: HLA-A were set to Carbamazepine Review for gene: HLA-A was set to GREEN Added comment: HLA-A*3101 Sources: Expert list |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||